The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patient preferences regarding bispecific antibody (BsAb) treatment schedules and clinical profiles in second-line or later (2L+) diffuse large B-cell lymphoma (DLBCL).
 
Zachary Frosch
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Amgen (Inst); Antegene (Inst); AstraZeneca (Inst); BeiGene (Inst); Genentech (Inst); Genmab (Inst); Merck (Inst); NCCN (Inst); Roche (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - NCCN
 
Anthony Masaquel
Employment - Genentech
Stock and Other Ownership Interests - Roche
Research Funding - The study was sponsored by Genentech, Inc.
 
Carolina Reyes
Employment - Genentech
Stock and Other Ownership Interests - Roche
 
Lourenia Cassoli
Employment - Genentech
Stock and Other Ownership Interests - Roche
 
Dominic Lai
Employment - Roche/Genentech
Stock and Other Ownership Interests - Roche
Other Relationship - Roche/Genentech
 
Andrea Lo-Rossi
Employment - Genentech
Stock and Other Ownership Interests - Roche
 
Kelley Myers
Other Relationship - Kelley Myers is an employee of RTI Health Solutions, a not for profit research institute which conducts research for the pharmaceutical industry. Her salary is unconnected to the projects on which she works and the details of the financial arrangements ar
 
Cooper Bussberg
Other Relationship - Cooper Bussberg is an employee of RTI Health Solutions, a not for profit research institute which conducts research for the pharmaceutical industry. His salary is unconnected to the projects on which he works and the details of the financial arrangements
 
Krish Patel
Consulting or Advisory Role - Abbvie; Abbvie (Inst); Adaptive Biotechnologies (Inst); ADC Therapeutics; Arcus Biosciences (Inst); AstraZeneca; AstraZeneca (Inst); AvenCell (Inst); BeiGene; BeOne Medicines (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb/Celgene/Juno (Inst); Caribou Biosciences; Caribou Biosciences (Inst); Century Therapeutics (Inst); Foresight Diagnostics (Inst); Genentech (Inst); Genentech/Roche; Genmab (Inst); Janssen (Inst); Kite, a Gilead company; Legend Biotech (Inst); Lilly; Loxo/Lilly (Inst); Lyell Immunopharma (Inst); Merck; Merck (Inst); Nurix; Pfizer; Sana Biotechnology; Sanofi (Inst)
Speakers' Bureau - Bristol-Myers Squibb; Kite, a Gilead company
Research Funding - Abbvie (Inst); Adaptive Biotechnologies (Inst); Adicet Bio (Inst); Arvinas (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); CRISPR Therapeutics (Inst); Fate Therapeutics (Inst); Indapta Therapeutics (Inst); Janssen (Inst); Kite/Gilead (Inst); Loxo/Lilly (Inst); MEI Pharma (Inst); Merck (Inst); Nurix (Inst); Pfizer (Inst); Pharmacyclics (Inst); Roche/Genentech (Inst); Sana Biotechnology (Inst); Treeline Biosciences (Inst); Xencor (Inst)